roxadustat

Roxadustat is a first-in-class, orally administered small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor used to treat symptomatic anemia associated with chronic kidney disease (CKD). It works by inhibiting the prolyl hydroxylase domain enzymes (PHD1, PHD2, and PHD3), which prevents the degradation of hypoxia-inducible factor alpha subunits. This stabilization increases endogenous erythropoietin production, stimulates erythropoiesis, improves iron availability, and reduces hepcidin levels. Roxadustat is approved for use in adults with anemia due to CKD in several regions including China, Japan, Europe, and other countries. The drug was developed by FibroGen in partnership with AstraZeneca and Astellas[1][2][3][6][7].

Brand names

EvrenzoEvrezo

Other names

roxadustatum